

UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. MBHB04-105-A (400/149))

PATENT

IN THE APPLICATION OF:

McSwiggen, et al.

Serial No. 10/824,036

Filed: April 14, 2004

Title RNA Interference Mediated
Treatment Of Polyglutamine (PolyQ)
Repeat Expansion Diseases Using
Short Interfering Nucleic Acid (siNA)

)
)
) Examiner: To Be Assigned
)
) Group Art Unit: 1645
)
) Confirmation No.: 6045
)
) Fax No.: (703) 746-9195
)

FACSIMILE TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attn: Office of Initial Patent Examination
Filing Receipt Corrections

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:
 - a) Request for Corrected Filing Receipt;
 - b) Copy of Filing Receipt with changes noted thereon;
 - c) Return postcard
2. With respect to fees:
 - a) It is believed no fee is due at this time.
3. **GENERAL AUTHORIZATION:** Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.


MCDONNELL BOEVEN FULMERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001
FACSIMILE (312) 913-0002

4. CERTIFICATE UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being transmitted with the USPTO facsimile number 703/746-9191, according to 37 CFR § 1.6(d) addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, ATTN: Office of Initial Patent Examination's Filing Receipt Corrections, on this 12 day of October, 2004.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

Date: October 12, 2004

By:



Lisa M.W. Hillman
Registration No. 43,673

UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. MBHB04-105-A (400/149))

PATENT

IN THE APPLICATION OF:

McSwiggen, et al.

Serial No. 10/824,036

Filed: April 14, 2004

Title RNA Interference Mediated
Treatment Of Polyglutamine (PolyQ)
Repeat Expansion Diseases Using
Short Interfering Nucleic Acid (siNA)

)
)
) Examiner: To Be Assigned
)
) Group Art Unit: 1645
)
) Confirmation No.: 6045
)
) Fax No.: (703) 746-9195
)

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attention: Office of Initial Patent Examination's
Filing Receipts Corrections

Dear Sir:

1. Attached is a copy of the filing receipt received from the PTO in the above-referenced application for which issuance of a new corrected filing receipt is respectfully requested.
2. There is an error with respect to the following data, which is incorrectly entered.
Error in
Foreign Applications:

Correct Data

Foreign Applications:

UNITED STATES OF AMERICA PCT/US03/05346 02/20/2003

MCDONNELL BOKREYEN HILBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001
FACSIMILE (312) 913-0002

UNITED STATES OF AMERICA PCT/US03/05028 02/20/2003
UNITED STATES OF AMERICA PCT/US02/15876 05/20/2002

3. The correction is not due to any error by applicant and no fee is due.

Respectfully submitted,
McDonnell, Boenken, Hulbert & Berghoff LLP

Date: October 12, 2004

By: 

Lisa M.W. Hillman
Registration No. 43,673



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/824,036	04/14/2004	1645	484	MBHB04-105-A (400.149)	25	31	1

020306
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 S. WACKER DRIVE
32ND FLOOR
CHICAGO, IL 60606

CONFIRMATION NO. 6045

FILING RECEIPT



0C000000013529730

DOCKETED

AUG 17 2004
DUE DATE 11/14/04 11/14/05
BY [Signature]

Date Mailed: 08/13/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

James McSwiggen, Boulder, CO;

Assignment For Published Patent Application

Sirna Therapeutics, Inc., Boulder, CO;

Domestic Priority data as claimed by applicant

This application is a CIP of 10/783,128 02/20/2004
which is a CIP of 10/757,803 01/14/2004
which is a CIP of 10/720,448 11/24/2003
which is a CIP of 10/693,059 10/23/2003
which is a CIP of 10/444,853 05/23/2003
and is a CIP of 10/652,791 08/29/2003
which is a CON of 10/422,704 04/24/2003
which is a CON of 10/417,012 04/16/2003
This application 10/824,036
is a CIP of PCT/US03/05346 02/20/2003
and is a CIP of PCT/US03/05028 02/20/2003
and said PCT/US03/05346 02/20/2003
claims benefit of 60/358,580 02/20/2002
and said PCT/US03/05028 02/20/2003
claims benefit of 60/358,580 02/20/2002
and said PCT/US03/05346 02/20/2003
claims benefit of 60/363,124 03/11/2002
and said PCT/US03/05028 02/20/2003
claims benefit of 60/363,124 03/11/2002

and said PCT/US03/05346 02/20/2003
claims benefit of 60/386,782 06/06/2002
and said PCT/US03/05028 02/20/2003
claims benefit of 60/386,782 06/06/2002
and said PCT/US03/05346 02/20/2003
claims benefit of 60/406,784 08/29/2002
and said PCT/US03/05028 02/20/2003
claims benefit of 60/406,784 08/29/2002
and said PCT/US03/05346 02/20/2003
claims benefit of 60/408,378 09/05/2002
and said PCT/US03/05028 02/20/2003
claims benefit of 60/408,378 09/05/2002
and said PCT/US03/05346 02/20/2003
claims benefit of 60/409,293 09/09/2002
and said PCT/US03/05028 02/20/2003
claims benefit of 60/409,293 09/09/2002
and said PCT/US03/05346 02/20/2003
claims benefit of 60/440,129 01/15/2003
and said PCT/US03/05028 02/20/2003
claims benefit of 60/440,129 01/15/2003
This application 10/824,036
is a CIP of 10/427,160 04/30/2003
and is a CIP of PCT/US02/15876 05/20/2002 *

(*)Data provided by applicant is not consistent with PTO records.

Foreign Applications

UNITED STATES OF AMERICA PCT/US03/05346 02/20/2003
UNITED STATES OF AMERICA PCT/US03/05028 02/20/2003
UNITED STATES OF AMERICA PCT/US02/15876 05/20/2002

If Required, Foreign Filing License Granted: 08/11/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using
short interfering nucleic acid (siNA)

Preliminary Class

435

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).